

The A1c Lowering Effect Prediction on The Basis of The Ediazzer Study

Valeh A. Mirzazada ^{1*}, Ramila A. Huseynova ¹, Sevil A ¹

¹ Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev, Baku, Azerbaijan.

***Corresponding Author:** Valeh A. Mirzazada, Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev, Baku, Azerbaijan.

Received date: September 12, 2022; Accepted date: September 15, 2022; Published date: September 21, 2022

Citation: Richmond R Gomes (2022). Multiple Splanchnic Venous Thromboses: A Fatal Complication of Recurrent Pancreatitis. *International Journal of Clinical Therapeutics*. 1(1); DOI:10.31579/ijct-2022/005

Copyright: © 2022 Valeh A. Mirzazada, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The optimization and predictability of metformin and sulfonylurea therapy remains relevant especially for low- and middle-income countries.

The purpose of this study was to create equations for predicting changes in glycohemoglobin during monotherapy by gliclazide MR or combination therapy by Gliclazide MR plus Metformin in DM2.

Material and Methods.

The data of 105 patients with DM2 who took part in the EdiAzer Study were analyzed. Subjects were required to make six visits to the center at Weeks 0 (W0), 2 (W2), 4 (W4), 6 (W6), 8 (W8), and 16 (W16). HbA1c levels were measured at Weeks 0 and 16. Fasting plasma glucose (FPG), height, weight, body mass index, and blood pressure were measured at all visits.

Results: "Success of Glucose-Lowering Effect" (SGLE), which should mean the difference between HbA1 values at the start (W0) and at the end (W16) of the study. Statistically significant correlation between SGLE and FGW0 ($r = +0,38$; $p < 0,001$); the difference between FGW0 and FGW2 ($r = +0,44$; $p < 0,001$); the difference between FGW2 and FGW4 ($r = +0,28$; $p < 0,01$); HbA1c W0 ($r = +0,70$; $p < 0,0001$) was shown. 6 models were constructed that allow predicting the results of 4 months treatment.

Conclusion: Although it is generally accepted that HbA1c should be checked every 3 months, checking it once every 4 months also gives quite a predictable result. Already at the end of the first month of treatment it is possible to predict the result of changes in HbA1c after 16 weeks of treatment. To do this, it is necessary to have on hand such indicators as HbA1cW0, FGW0, FGW2, FGW4. The most accurate prediction result is achieved when using all these parameters in a complex (Preform DiA1c6 index).

Keywords: diabetes mellitus; A1c; fasting glucose; glucose lowering effect prediction; Gliclazide MR; metformin

Abbreviations:

DM – diabetes mellitus

DM2 – diabetes mellitus type 2 FPG – fasting plasma glucose

FPGW0 – fasting plasma glucose at the start of the study FPGW2 – fasting plasma glucose at the point W2

FPGW4 – fasting plasma glucose at the point W4 SGLE – Success of Glucose-Lowering Effect

HbA1cW0 – Glycated Hemoglobin at the start of the study (week 0)
HbA1cW16 – Glycated Hemoglobin at the end of the study (week 16)
Preform DiA1c – Predictive Four Months Difference in HbA1c

SD – standard deviation

W0 – the start of the study (week 0)

W2 – week 2 or the second week after the study start **W4** – week 4 or the fourth week after the study start **W6** – week 6 or the sixth week after the study start **W8** – week 8 or the eighth week after the study start

W16 – week 16 or the sixteenth ---- the final week of the study

Introduction

An estimated 537 million adults, or 10.5% of the world's population, aged 20–79 years are currently living with diabetes (DM). The total number is predicted to rise to 643 million (11.3%) by 2030 and to 783 million (12.2%) by 2045 [1].

Simple calculations of the IDF Diabetes Atlas data [1] show that the number of people with diabetes will increase by 13.8 million in high-income countries (according to the World Bank income classification), by 2093 million in middle-income countries and by 23.5 million in low-income countries. The total number of people with diabetes living in low- and middle-income countries will increase from 432.7 million in 2021 to 665.5 million by 2045. The proportion of people with diabetes living in middle- and low-income countries will increase from 80.6% in 2021 to 85.0% by 2045.

Type 2 diabetes (DM2) accounts for the vast majority (over 90%) of diabetes [1,2]. Blood glucose control is an essential component of an integrated approach to diabetes management [2–4].

The first-line drug position gradually moves from metformin to GLP-1 RA and SGLT2 inhibitors [2,3], since these medications, along with the glucose-lowering effect, also have a cardio- and reno-protective effect, reduce body weight and are relatively safe against hypoglycemia [2,3,4]. However, these new and very promising drugs are expensive and the majority of patients in the world continue to receive treatment with metformin and sulfonylureas [5].

Thus, the problem of optimization and predictability of metformin and sulfonylurea therapy remains relevant. In accordance with modern

recommendations, initiation of glucose lowering therapy can begin as monotherapy [2–4] and as combine therapy [3]. Previously we analyzed results of monotherapy by gliclazide MR or combination therapy by Gliclazide MR plus Metformin in DM2 (EdiAzer Study) [6]. The study presented in this article was conducted on the basis of EdiAzer Study data.

The purpose of this study was to create equations for predicting changes in glycohemoglobin during monotherapy by gliclazide MR or combination therapy by Gliclazide MR plus Metformin in DM2.

Materials and Methods

EdiAzer was an open-label, non-comparative observational study consisting of a 2-month inclusion period and 4 months of follow-up. The study was conducted according to the standards and principles of the Declaration of Helsinki. Ethical approval was site specific, and written informed consent was obtained from all patients at the inclusion visit. The trial was registered on the ClinicalTrials.gov website with the number NCT03164187.

The study recruited: treatment-naïve patients with newly diagnosed DM2; patients without pharmacotherapy which were uncontrolled despite diet and physical activity; patients uncontrolled with metformin monotherapy for whom treating physicians had already decided to prescribe gliclazide MR. Detailed information about the study, the criteria for inclusion in the study and exclusion from it was presented in a previous publication [6].

The flow of participants through the study is shown in Figure 1.




Figure 1: The flow of participants through the study EdiAzer

Subjects were required to make six visits to the center at Weeks 0 (W0), 2 (W2), 4 (W4), 6 (W6), 8 (W8), and 16 (W16). HbA1c levels were measured at Weeks 0 and 16. Fasting plasma glucose (FPG), height, weight, body mass index, and blood pressure were measured at all visits.

Patient demographics and baseline characteristics were shown early [6].

Statistical analysis: Quantitative variables were summarized by mean standard deviation. Correlation analysis and multiple linear regression method were used [7]. Chi-square or Fisher exact tests were used to determine the statistical significance of differences between proportions [8]. Student t tests for paired samples were used to compare mean values over time. A p value < 0.05 was considered statistically significant.

Results

To simplify the discussion of the results obtained, we introduce the term "Success of Glucose-Lowering Effect" (SGLE), which should mean the difference between HbA1c values at the start (W0) and at the end (W16) of the study. That is

$$\text{SGLE} = \text{HbA1c}_{W0} - \text{HbA1c}_{W16}$$

Since it is a priori known that SGLE is the resulting parameter, the use of correlation analysis gives us the opportunity to determine the degree of various factors influence on SGLE.

We have studied the influence of factors such as the age of the study participants, duration of DM, complications of DM, height, weight at W0 and W16, body mass index at points W0 and W16, systolic and diastolic blood pressure on the values of SGLE. In all these cases, the values of the correlation coefficients were not statistically significant ($p > 0.05$).

Doses of gliclazide MR and/or metformin at the end of the EdiAzer study (W16) also had no statistically significant ($p > 0.05$) effect on the values of SGLE.




Figure 2: Correlation between SGLE and FG_{W0} ; SGLE and difference of FG_{W0} and FG_{W2} ; SGLE and difference of FG_{W2} and FG_{W4} ; SGLE and $HbA1c_{W0}$

As can be seen from Fig. 2, a statistically significant correlation between SGLE on the one hand and FG_{W0} ($r = +0,38$; $p < 0,001$); the difference between FG_{W0} and FG_{W2} ($r = +0,44$; $p < 0,001$); the difference between FG_{W2} and FG_{W4} ($r = +0,28$; $p < 0,01$); $HbA1c_{W0}$ ($r = +0,70$; $p < 0,0001$). In this regard, using the linear regression method, 6 models were constructed that allow predicting the values of 4 months (16 weeks) after the start of

monotherapy with gliclazide MR and/or combination therapy with gliclazide MR plus metformin.

The calculated indicator SGLE, obtained as a result of using the model, was named by us Preform DiA1c (Predictive Four Months Difference in HbA1c). These models are presented in Table 1.

Model 1:	$\text{Preform DiA1c1} = 0.1014 * \text{FG W0} + 0.08633$
Model 2:	$\text{Preform DiA1c2} = 0.1713 * (\text{FG W0} \dots \text{FGW2}) + 0.82531$
Model 3:	$\text{Preform DiA1c3} = 0.2234 * (\text{FG W2} \dots \text{FGW4}) + 0.99988$
Model 4:	$\text{Preform DiA1c4} = 0.4594 * \text{HbA1c W0} - 0.86889$
Model 5:	$\text{Preform DiA1c5} = 1.02552 - 0.0355 * \text{FG W0} + 0.1926 * (\text{FG W0} \dots \text{FGW2}) + 0.1691 * (\text{FG W2} \dots \text{FGW4})$
Model 6:	$\text{Preform DiA1c6} = -1.93608 - 0.1647 * \text{FG W0} + 0.2414 * (\text{FG W0} - \text{FGW2}) + 0.2273 * (\text{FG W2} - \text{FGW4}) + 0.4472 \text{HbA1c W0}$

Table 1: statistical Models for prediction of the difference between HbA1c at the start of therapy by Gliclazide MR and/or Gliclazide MR plus Metformin and after four months of therapy.

Figure 3 shows the results of the correlation analysis of the relationships between SGLE and PreformDiA1c indicators obtained in accordance with models 1-6.




Figure 3: Correlation between SGLE and Preform DiA1c indicators obtained in accordance with models 1-6.

As can be seen from Figure 3, the correlation coefficient was minimal for Model 3 ($r = +0,29$; $p < 0,01$) and maximal for model 6 ($r = +0,80$; $p < 0,001$). Figure 4 shows the values of the standard deviation (SD) of the difference

between the SGLE values, that is, the real HbA1cw16 and the values of the predicted by models 1-6 HbA1c (Preform DiA1c).




Figure 4: Values of the standard deviation (SD) of the difference between the SGLE values, that is, the realHbA1cw16 and the values of the predicted by models 1-6 HbA1c (Preform DiA1c).

As expected, the average values of the difference between SGLE and Preform DiA1c were equal to 0 in all 6 groups. From Figure 4, it can be seen that the smallest SD occurred when using Model 6. This shows the minimal spread of data typical for calculations based on this model, the greatest proximity of the results of calculation by Model 6 (Preform

DiA1c) to the actual SGLE.

Next, we studied the absolute values of the differences between SGLE and Preform DiA1c calculation by Models 1-6.

Figure 5 shows the average of the absolute values of the difference between SGLE and Preform DiA1c calculation by Models 1-6.




Figure 5: Average of the absolute values of the difference between SGLE and Preform DiA1c calculation by Models 1-6. It can be seen from Figure 5 that the smallest absolute values of the difference between SGLE and Preform DiA1c were characteristic of the model 6. Moreover, the differences between model 6 results and results of models 1, 2, 3, 5 were statistically significant (in all cases $p < 0.001$).

Discussion

The establishment of individual glucose management goals is the basis on which further glucose-lowering therapy is based. The main target indicator is a more stable HbA1c [2]. The generally accepted standard is the definition of a level HbA1c one time in three months [2,3,4] and this is due to the fact that the average duration of red blood cell circulation is 120 days [9]. However, in recent years, doubts have been raised about the absolute validity of the 120-day period [10]. In the EdiAzer Study HbA1c determined 1 time in 4 months [5]. The results presented in this article demonstrate that even when determining 1 every 4 months, HbA1c remains a completely predictable indicator.

The possibility to reduce the HbA1c definitions number for each DM2 patient from 4 times per year to 3 times per year may be economically

feasible, especially for low- and middle-income countries.

At the same time, less frequent monitoring of HbA1c increases the need for greater predictability of expected results and control of the adequacy of the results obtained to the set target parameters.

Our research has shown that at the end of the first month treatment by Gliclize MR or Metformin + Gliclize MR, it is possible to predict HbA1c changes after 4 months of treatment. To do this, it is necessary to have on hand such indicators as HbA1cw0, FGW0, FGW2, FGW4. The most accurate prediction result is achieved when using all these parameters in a complex (Preform DiA1c6)

The possibility of prediction also means the possibility of timely correction

of therapy. This is especially important for those cases where the results of the received prognosis do not correspond to the goals of treatment.

Acknowledgement

We thank the participants of this study.

Conflict of Interest

This study was supported by Servier. Medical writing support was provided by Jenny Grice, a freelance medical writer, and funded by Servier.

References

1. IDF Diabetes Atlas 10th edition. (2021). International Diabetes Federation.
2. American Diabetes Association. (2022). Standards of Medical Care in Diabetes. *Diabetes Care*, 45(Supplement 1):S1----S264.
3. Garber A.J., Handelsman Y., Grunberger G., Einhorn D., Abrahamson M.J. et al. (2020). Consensus Statement by the American Association of Clinical Endocrinologists and American College of
4. Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2020 Executive Summary. *Endocrine Practice*, 26(1):107----139
5. Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Cheriello A. et al. (2019). ESC Guidelines on diabetes, pre----diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force for diabetes, pre----diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *European Heart Journal*, 41:255----323
6. O'Donoghue M.L., Kato E.T., Mosenson O., Murphy S.A., Cahn A. et al. (2021). The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. *Diabetologia*, 64(6),1226----1234.
7. Mirzazada V.A., Huseynova R.A., Mustafayeva S.A., Gasimova F.N., Ahmadova U. et al. (2020). Evaluation of Type 2 Diabetes Treatment with Gliclazide Modified Release in Azerbaijan (the EdiAzer Study): Results from a 16----week Observational Clinical Study. *Journal of Diabetology*, 11(3):175----182.
8. Social Science Statistics. Statistics Calculators. (2020).
9. Stats.Blue.
10. Nitin S. (2010). HbA1c and factors other than diabetes mellitus affecting it. *Singapore Med J.*, 51:616----622.
11. Fernandez A. C., Fernandez A. C. (2017). How do red blood cells know when to die? *R. Soc. open sci.*, 4(4):1----12

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <https://clinicsearchonline.org/journals/international-journal-of-clinical-therapeutics>



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.